Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Blood (2015)
  • Joseph G. Jurcic, Columbia University Medical Center
  • Farhad Ravandi, University of Texas MD Anderson Cancer Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jae H. Park, Memorial Sloan Kettering Cancer Center
  • B. Douglas Smith, Johns Hopkins University
  • Moshe Yair Levy, Texas Oncology
  • Elihu H. Estey, Fred Hutchinson Cancer Research Center
  • Alexander E. Perl, University of Pennsylvania
  • Hagop Kantarjian, University of Texas MD Anderson Cancer Center
  • Dennis Earle
  • Dragan Cicic
  • David A. Scheinberg, Memorial Sloan Kettering Cancer Center
Link
Disciplines
Publication Date
December 3, 2015
Citation Information
Joseph G. Jurcic, Farhad Ravandi, John M. Pagel, Jae H. Park, et al.. "Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)" Blood Vol. 126 Iss. 23 (2015) p. 3794 - 3794
Available at: http://works.bepress.com/john-pagel/63/